-
1
-
-
2942751868
-
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II
-
Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6:499-506.
-
(2004)
Nat Cell Biol
, vol.6
, pp. 499-506
-
-
Zou, Y.1
Akazawa, H.2
Qin, Y.3
Sano, M.4
Takano, H.5
Minamino, T.6
Makita, N.7
Iwanaga, K.8
Zhu, W.9
Kudoh, S.10
Toko, H.11
Tamura, K.12
Kihara, M.13
Nagai, T.14
Fukamizu, A.15
Umemura, S.16
Iiri, T.17
Fujita, T.18
Komuro, I.19
-
2
-
-
33745842894
-
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor
-
Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, Tomita S, Uehara Y, Karnik SS, Yanagisawa H, Koike H, Komuro I, Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281:19288-19295.
-
(2006)
J Biol Chem
, vol.281
, pp. 19288-19295
-
-
Miura, S.1
Fujino, M.2
Hanzawa, H.3
Kiya, Y.4
Imaizumi, S.5
Matsuo, Y.6
Tomita, S.7
Uehara, Y.8
Karnik, S.S.9
Yanagisawa, H.10
Koike, H.11
Komuro, I.12
Saku, K.13
-
3
-
-
38049049272
-
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state
-
Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, Karnik SS, Saku K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22:139-146.
-
(2008)
Mol Endocrinol
, vol.22
, pp. 139-146
-
-
Miura, S.1
Kiya, Y.2
Kanazawa, T.3
Imaizumi, S.4
Fujino, M.5
Matsuo, Y.6
Karnik, S.S.7
Saku, K.8
-
4
-
-
20444418116
-
Molecular-specific effects of angiotensin II antagonists: Clinical relevance to treating hypertension?
-
Reid JL. Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? J Renin Angiotensin Aldosterone Syst 2005; 6:15-24.
-
(2005)
J Renin Angiotensin Aldosterone Syst
, vol.6
, pp. 15-24
-
-
Reid, J.L.1
-
5
-
-
34547489857
-
Uric acid reduction: A new paradigm in the management of cardiovascular risk?
-
Dawson J, Quinn T, Walters M. Uric acid reduction: a new paradigm in the management of cardiovascular risk? Curr Med Chem 2007; 14:1879-1886.
-
(2007)
Curr Med Chem
, vol.14
, pp. 1879-1886
-
-
Dawson, J.1
Quinn, T.2
Walters, M.3
-
6
-
-
18244367869
-
Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis
-
Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2:e76.
-
(2005)
PLoS Med
, vol.2
-
-
Wheeler, J.G.1
Juzwishin, K.D.2
Eiriksdottir, G.3
Gudnason, V.4
Danesh, J.5
-
8
-
-
1542510891
-
Uric acid: Role in cardiovascular disease and effects of losartan
-
Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20:369-379.
-
(2004)
Curr Med Res Opin
, vol.20
, pp. 369-379
-
-
Alderman, M.1
Aiyer, K.J.2
-
9
-
-
40549090278
-
Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers
-
Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, Tamai I. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res 2008; 25:639-646.
-
(2008)
Pharm Res
, vol.25
, pp. 639-646
-
-
Sato, M.1
Iwanaga, T.2
Mamada, H.3
Ogihara, T.4
Yabuuchi, H.5
Maeda, T.6
Tamai, I.7
-
10
-
-
33845887252
-
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter
-
Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320:211-217.
-
(2007)
J Pharmacol Exp Ther
, vol.320
, pp. 211-217
-
-
Iwanaga, T.1
Sato, M.2
Maeda, T.3
Ogihara, T.4
Tamai, I.5
-
11
-
-
0028593665
-
Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension
-
Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7:1035-1040.
-
(1994)
Am J Hypertens
, vol.7
, pp. 1035-1040
-
-
Sweet, C.S.1
Bradstreet, D.C.2
Berman, R.S.3
Jallard, N.4
Saenz, A.5
Weidler, D.J.6
-
12
-
-
33847421488
-
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
-
Devereux RB, Dahlöf B. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 2007; 23:443-457.
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 443-457
-
-
Devereux, R.B.1
Dahlöf, B.2
-
13
-
-
10744221128
-
LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study
-
Høieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65:1041-1049.
-
(2004)
Kidney Int
, vol.65
, pp. 1041-1049
-
-
Høieggen, A.1
Alderman, M.H.2
Kjeldsen, S.E.3
Julius, S.4
Devereux, R.B.5
De Faire, U.6
Fyhrquist, F.7
Ibsen, H.8
Kristianson, K.9
Lederballe-Pedersen, O.10
Lindholm, L.H.11
Nieminen, M.S.12
Omvik, P.13
Oparil, S.14
Wedel, H.15
Chen, C.16
Dahlöf, B.17
-
14
-
-
0015829488
-
Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis
-
Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180:1332-1339.
-
(1973)
Science
, vol.180
, pp. 1332-1339
-
-
Ross, R.1
Glomset, J.A.2
-
15
-
-
0028970042
-
Cell biology of atherosclerosis
-
Ross R. Cell biology of atherosclerosis. Ann Rev Physiol 1995; 57:791-804.
-
(1995)
Ann Rev Physiol
, vol.57
, pp. 791-804
-
-
Ross, R.1
-
16
-
-
33846362954
-
Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system
-
Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
-
(2007)
Am J Physiol Cell Physiol
, vol.292
-
-
Mehta, P.K.1
Griendling, K.K.2
-
17
-
-
0026499001
-
Factors controlling smooth-muscle cell proliferation
-
Reidy MA. Factors controlling smooth-muscle cell proliferation. Arch Pathol Lab Med 1992; 116:1276-1280.
-
(1992)
Arch Pathol Lab Med
, vol.116
, pp. 1276-1280
-
-
Reidy, M.A.1
-
18
-
-
42049108222
-
Inhibition of cardiovascular cell proliferation by angiotensin receptor antagonists: Are all molecules the same?
-
Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor antagonists: are all molecules the same? J Hypertens 2008; 26:973-980.
-
(2008)
J Hypertens
, vol.26
, pp. 973-980
-
-
Benson, S.C.1
Iguchi, R.2
Ho, C.I.3
Yamamoto, K.4
Kurtz, T.W.5
-
19
-
-
1542547460
-
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
-
Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43:993-1002.
-
(2004)
Hypertension
, vol.43
, pp. 993-1002
-
-
Benson, S.C.1
Pershadsingh, H.A.2
Ho, C.I.3
Chittiboyina, A.4
Desai, P.5
Pravenec, M.6
Qi, N.7
Wang, J.8
Avery, M.A.9
Kurtz, T.W.10
-
20
-
-
2442451618
-
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity
-
Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 2004; 109:2054-2057.
-
(2004)
Circulation
, vol.109
, pp. 2054-2057
-
-
Schupp, M.1
Janke, J.2
Clasen, R.3
Unger, T.4
Kintscher, U.5
-
21
-
-
0035146287
-
Control of vascular cell proliferation and migration by PPAR-γ: A new approach to the macrovascular complications of diabetes
-
Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24:392-397.
-
(2001)
Diabetes Care
, vol.24
, pp. 392-397
-
-
Hsueh, W.A.1
Jackson, S.2
Law, R.E.3
-
22
-
-
0026689544
-
DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors
-
Liu EC, Hedberg A, Goldenberg HJ, Harris DN, Webb ML. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1992; 44:89-99.
-
(1992)
Prostaglandins
, vol.44
, pp. 89-99
-
-
Liu, E.C.1
Hedberg, A.2
Goldenberg, H.J.3
Harris, D.N.4
Webb, M.L.5
-
23
-
-
0030911212
-
Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries
-
Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281:1065-1070.
-
(1997)
J Pharmacol Exp Ther
, vol.281
, pp. 1065-1070
-
-
Li, P.1
Ferrario, C.M.2
Brosnihan, K.B.3
-
24
-
-
0033981547
-
Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation
-
Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000; 292:238-246.
-
(2000)
J Pharmacol Exp Ther
, vol.292
, pp. 238-246
-
-
Li, P.1
Fukuhara, M.2
Diz, D.I.3
Ferrario, C.M.4
Brosnihan, K.B.5
-
25
-
-
0034564087
-
Inhibition of platelet aggregability by losartan in essential hypertension
-
Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86:1188-1192.
-
(2000)
Am J Cardiol
, vol.86
, pp. 1188-1192
-
-
Levy, P.J.1
Yunis, C.2
Owen, J.3
Brosnihan, K.B.4
Smith, R.5
Ferrario, C.M.6
-
26
-
-
0035072743
-
The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo
-
Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J Hypertens 2001; 19(3 Pt 2):561-566.
-
(2001)
J Hypertens
, vol.19
, Issue.3 PART 2
, pp. 561-566
-
-
Fukuhara, M.1
Neves, L.A.2
Li, P.3
Diz, D.I.4
Ferrario, C.M.5
Brosnihan, K.B.6
-
27
-
-
0034211530
-
Losartan inhibits in vitro platelet activation: Comparison with candesartan and valsartan
-
Nunez A, Gomez J, Zalba LR, Monton M, Jimenez A, Velasco S, Lopez-Blaya A, Uriarte AC, Casado S, Lopez-Farre A. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000; 1:175-179.
-
(2000)
J Renin Angiotensin Aldosterone Syst
, vol.1
, pp. 175-179
-
-
Nunez, A.1
Gomez, J.2
Zalba, L.R.3
Monton, M.4
Jimenez, A.5
Velasco, S.6
Lopez-Blaya, A.7
Uriarte, A.C.8
Casado, S.9
Lopez-Farre, A.10
-
28
-
-
0035082059
-
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: Comparison of losartan, candesartan, and valsartan
-
Jimenez AM, Monton M, Garcia R, Nunez A, Gomez J, Rico L, Garcia-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farre J, Casado S, Lopez-Farre A. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. J Cardiovasc Pharmacol 2001; 37:406-412.
-
(2001)
J Cardiovasc Pharmacol
, vol.37
, pp. 406-412
-
-
Jimenez, A.M.1
Monton, M.2
Garcia, R.3
Nunez, A.4
Gomez, J.5
Rico, L.6
Garcia-Colis, E.7
de Miguel, L.S.8
Arriero, M.M.9
Cabestrero, F.10
Farre, J.11
Casado, S.12
Lopez-Farre, A.13
-
29
-
-
34249859312
-
Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers
-
Sato Y, Fujii S, Imagawa S, Ohmura K, Ohmura Y, Andoh Y, Dong J, Ishimori N, Furumoto T, Tsutsui H. Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J Atheroscler Thromb 2007; 14:31-35.
-
(2007)
J Atheroscler Thromb
, vol.14
, pp. 31-35
-
-
Sato, Y.1
Fujii, S.2
Imagawa, S.3
Ohmura, K.4
Ohmura, Y.5
Andoh, Y.6
Dong, J.7
Ishimori, N.8
Furumoto, T.9
Tsutsui, H.10
-
30
-
-
34247372574
-
EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: Potential impact on atherothrombosis
-
Grothusen C, Umbreen S, Konrad I, Stellos K, Schulz C, Schmidt B, Kremmer E, Teebken O, Massberg S, Luchtefeld M, Schieffer B, Gawaz M. EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. Arterioscler Thromb Vasc Biol 2007; 27:1184-1190.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 1184-1190
-
-
Grothusen, C.1
Umbreen, S.2
Konrad, I.3
Stellos, K.4
Schulz, C.5
Schmidt, B.6
Kremmer, E.7
Teebken, O.8
Massberg, S.9
Luchtefeld, M.10
Schieffer, B.11
Gawaz, M.12
-
31
-
-
0037134412
-
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179
-
Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Boger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90:770-776.
-
(2002)
Circ Res
, vol.90
, pp. 770-776
-
-
Kramer, C.1
Sunkomat, J.2
Witte, J.3
Luchtefeld, M.4
Walden, M.5
Schmidt, B.6
Tsikas, D.7
Boger, R.H.8
Forssmann, W.G.9
Drexler, H.10
Schieffer, B.11
-
32
-
-
0038101440
-
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites
-
Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003; 46:2261-2270.
-
(2003)
J Med Chem
, vol.46
, pp. 2261-2270
-
-
Schmidt, B.1
Schieffer, B.2
-
33
-
-
25444531421
-
Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: Angiotensin II type 1 receptor-independent effects of EXP3179
-
Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 2005; 112:1798-1805.
-
(2005)
Circulation
, vol.112
, pp. 1798-1805
-
-
Watanabe, T.1
Suzuki, J.2
Yamawaki, H.3
Sharma, V.K.4
Sheu, S.S.5
Berk, B.C.6
-
34
-
-
34249325904
-
Atherosclerosis and oxidant stress: The end of the road for antioxidant vitamin treatment?
-
Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc Drugs Ther 2007; 21:195-210.
-
(2007)
Cardiovasc Drugs Ther
, vol.21
, pp. 195-210
-
-
Thomson, M.J.1
Puntmann, V.2
Kaski, J.C.3
-
35
-
-
34447315837
-
Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker
-
Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, Fujita T. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 2007; 25:1643-1649.
-
(2007)
J Hypertens
, vol.25
, pp. 1643-1649
-
-
Shao, J.1
Nangaku, M.2
Inagi, R.3
Kato, H.4
Miyata, T.5
Matsusaka, T.6
Noiri, E.7
Fujita, T.8
-
36
-
-
40949119482
-
Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells
-
Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198:22-28.
-
(2008)
Atherosclerosis
, vol.198
, pp. 22-28
-
-
Cianchetti, S.1
Del Fiorentino, A.2
Colognato, R.3
Di Stefano, R.4
Franzoni, F.5
Pedrinelli, R.6
-
37
-
-
33750913676
-
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation
-
Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation. Diabetologia 2006; 49:3094-3099.
-
(2006)
Diabetologia
, vol.49
, pp. 3094-3099
-
-
Yoshida, T.1
Yamagishi, S.2
Nakamura, K.3
Matsui, T.4
Imaizumi, T.5
Takeuchi, M.6
Koga, H.7
Ueno, T.8
Sata, M.9
-
38
-
-
36049002393
-
Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
-
Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117:3393-3402.
-
(2007)
J Clin Invest
, vol.117
, pp. 3393-3402
-
-
Wang, J.1
Ho, L.2
Chen, L.3
Zhao, Z.4
Zhao, W.5
Qian, X.6
Humala, N.7
Seror, I.8
Bartholomew, S.9
Rosendorff, C.10
Pasinetti, G.M.11
-
39
-
-
36448932405
-
Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid
-
Whitehead SN, Cheng G, Hachinski VC, Cechetto DF. Progressive increase in infarct size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke 2007; 38:3245-3250.
-
(2007)
Stroke
, vol.38
, pp. 3245-3250
-
-
Whitehead, S.N.1
Cheng, G.2
Hachinski, V.C.3
Cechetto, D.F.4
-
40
-
-
19244365650
-
Thiazolidinediones
-
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
-
(2004)
N Engl J Med
, vol.351
, pp. 1106-1118
-
-
Yki-Jarvinen, H.1
-
41
-
-
33748748206
-
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
-
Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.
-
(2006)
Lancet
, vol.368
, pp. 1096-1105
-
-
Gerstein, H.C.1
Yusuf, S.2
Bosch, J.3
Pogue, J.4
Sheridan, P.5
Dinccag, N.6
Hanefeld, M.7
Hoogwerf, B.8
Laakso, M.9
Mohan, V.10
Shaw, J.11
Zinman, B.12
Holman, R.R.13
-
42
-
-
10344249378
-
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system
-
Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22:2253-2261.
-
(2004)
J Hypertens
, vol.22
, pp. 2253-2261
-
-
Kurtz, T.W.1
Pravenec, M.2
-
43
-
-
33750825285
-
Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists
-
Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists. Vascular pharmacology 2006; 45:154-162.
-
(2006)
Vascular pharmacology
, vol.45
, pp. 154-162
-
-
Erbe, D.V.1
Gartrell, K.2
Zhang, Y.L.3
Suri, V.4
Kirincich, S.J.5
Will, S.6
Perreault, M.7
Wang, S.8
Tobin, J.F.9
-
44
-
-
33747438362
-
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation
-
Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation. J Hypertens 2006; 24:1809-1816.
-
(2006)
J Hypertens
, vol.24
, pp. 1809-1816
-
-
Janke, J.1
Schupp, M.2
Engeli, S.3
Gorzelniak, K.4
Boschmann, M.5
Sauma, L.6
Nystrom, F.H.7
Jordan, J.8
Luft, F.C.9
Sharma, A.M.10
-
45
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
46
-
-
26244453309
-
-
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
-
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
-
-
-
-
47
-
-
34548590934
-
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
-
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-1188.
-
(2007)
JAMA
, vol.298
, pp. 1180-1188
-
-
Lincoff, A.M.1
Wolski, K.2
Nicholls, S.J.3
Nissen, S.E.4
-
48
-
-
0034735992
-
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
-
Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278:704-711.
-
(2000)
Biochem Biophys Res Commun
, vol.278
, pp. 704-711
-
-
Sakamoto, J.1
Kimura, H.2
Moriyama, S.3
Odaka, H.4
Momose, Y.5
Sugiyama, Y.6
Sawada, H.7
-
49
-
-
0030602866
-
The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
-
Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302:93-109.
-
(1996)
Biochim Biophys Acta
, vol.1302
, pp. 93-109
-
-
Schoonjans, K.1
Staels, B.2
Auwerx, J.3
-
50
-
-
48449106424
-
Liver-specific PPARα-target gene regulation by the angiotensin type 1 receptor blocker telmisartan
-
Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific PPARα-target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008; 57:1405-1413.
-
(2008)
Diabetes
, vol.57
, pp. 1405-1413
-
-
Clemenz, M.1
Frost, N.2
Schupp, M.3
Caron, S.4
Foryst-Ludwig, A.5
Bohm, C.6
Hartge, M.7
Gust, R.8
Staels, B.9
Unger, T.10
Kintscher, U.11
-
51
-
-
33745253947
-
Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
-
Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006; 34:1109-1115.
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 1109-1115
-
-
Ishiguro, N.1
Maeda, K.2
Kishimoto, W.3
Saito, A.4
Harada, A.5
Ebner, T.6
Roth, W.7
Igarashi, T.8
Sugiyama, Y.9
-
52
-
-
0033873784
-
A review on telmisartan: A novel long-acting angiotensin II receptor antagonist
-
Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Gladigau V, Havel NH. A review on telmisartan: a novel long-acting angiotensin II receptor antagonist. Cardiovasc Drug Rev 2000; 18:127-156.
-
(2000)
Cardiovasc Drug Rev
, vol.18
, pp. 127-156
-
-
Wienen, W.1
Entzeroth, M.2
van Meel, J.C.A.3
Stangier, J.4
Busch, U.5
Ebner, T.6
Schmid, J.7
Lehmann, H.8
Matzek, K.9
Kempthorne-Rawson, J.10
Gladigau, V.11
Havel, N.H.12
-
53
-
-
33644672013
-
Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity
-
Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005; 54:3442-3452.
-
(2005)
Diabetes
, vol.54
, pp. 3442-3452
-
-
Schupp, M.1
Clemenz, M.2
Gineste, R.3
Witt, H.4
Janke, J.5
Helleboid, S.6
Hennuyer, N.7
Ruiz, P.8
Unger, T.9
Staels, B.10
Kintscher, U.11
-
54
-
-
33646148948
-
Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis
-
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47:1003-1009.
-
(2006)
Hypertension
, vol.47
, pp. 1003-1009
-
-
Sugimoto, K.1
Qi, N.R.2
Kazdova, L.3
Pravenec, M.4
Ogihara, T.5
Kurtz, T.W.6
-
55
-
-
4344569280
-
Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study
-
Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457-464.
-
(2004)
Hypertens Res
, vol.27
, pp. 457-464
-
-
Derosa, G.1
Ragonesi, P.D.2
Mugellini, A.3
Ciccarelli, L.4
Fogari, R.5
-
56
-
-
26944449731
-
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
-
Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4:6-9.
-
(2005)
Cardiovasc Diabetol
, vol.4
, pp. 6-9
-
-
Vitale, C.1
Mercuro, G.2
Castiglioni, C.3
Cornoldi, A.4
Tulli, A.5
Fini, M.6
Volterrani, M.7
Rosano, G.M.8
-
57
-
-
14644444519
-
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: Metabolic and antiatherogenic consequences
-
Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28:757-758.
-
(2005)
Diabetes Care
, vol.28
, pp. 757-758
-
-
Miura, Y.1
Yamamoto, N.2
Tsunekawa, S.3
Taguchi, S.4
Eguchi, Y.5
Ozaki, N.6
Oiso, Y.7
-
58
-
-
33846087364
-
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: Effects on insulin-resistance, leptin and tumor necrosis factor-α
-
Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertens Res 2006; 29:849-856.
-
(2006)
Hypertens Res
, vol.29
, pp. 849-856
-
-
Derosa, G.1
Cicero, A.F.2
D'Angelo, A.3
Ragonesi, P.D.4
Ciccarelli, L.5
Piccinni, M.N.6
Pricolo, F.7
Salvadeo, S.A.8
Ferrari, I.9
Gravina, A.10
Fogari, R.11
-
59
-
-
33745511931
-
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
-
Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vasc Pharmacol 2006; 45:19-28.
-
(2006)
Vasc Pharmacol
, vol.45
, pp. 19-28
-
-
Touyz, R.M.1
Schiffrin, E.L.2
-
60
-
-
38549161568
-
Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-γ
-
Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-γ. Hypertension 2008; 51:1-8.
-
(2008)
Hypertension
, vol.51
, pp. 1-8
-
-
Walcher, D.1
Hess, K.2
Heinz, P.3
Petscher, K.4
Vasic, D.5
Kintscher, U.6
Clemenz, M.7
Hartge, M.8
Raps, K.9
Hombach, V.10
Marx, N.11
-
61
-
-
33747402467
-
Telmisartan inhibits β2-integrin MAC-1 expression in human T-lymphocytes
-
Link A, Lenz M, Legner D, Bohm M, Nickenig G. Telmisartan inhibits β2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens 2006; 24:1891-1898.
-
(2006)
J Hypertens
, vol.24
, pp. 1891-1898
-
-
Link, A.1
Lenz, M.2
Legner, D.3
Bohm, M.4
Nickenig, G.5
-
62
-
-
36248953701
-
Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients
-
Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY, Lim DS. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100:1625-1629.
-
(2007)
Am J Cardiol
, vol.100
, pp. 1625-1629
-
-
Hong, S.J.1
Shim, W.J.2
Choi, J.I.3
Joo, H.J.4
Shin, S.Y.5
Park, S.M.6
Lim, S.Y.7
Lim, D.S.8
-
63
-
-
47649093164
-
Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice
-
in press
-
Blessing E, Preusch M, Kranzhofer R, Kinscherf R, Marx N, Rosenfeld ME, Isermann B, Weber CM, Kreuzer J, Grafe J, Katus HA, Bea F. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis, in press.
-
Atherosclerosis
-
-
Blessing, E.1
Preusch, M.2
Kranzhofer, R.3
Kinscherf, R.4
Marx, N.5
Rosenfeld, M.E.6
Isermann, B.7
Weber, C.M.8
Kreuzer, J.9
Grafe, J.10
Katus, H.A.11
Bea, F.12
-
64
-
-
39749201501
-
Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system. role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor γ signaling during endothelial aging
-
Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system. role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor γ signaling during endothelial aging. Hypertension 2008; 51:696-703.
-
(2008)
Hypertension
, vol.51
, pp. 696-703
-
-
Scalera, F.1
Martens-Lobenhoffer, J.2
Bukowska, A.3
Lendeckel, U.4
Tager, M.5
Bode-Boger, S.M.6
-
65
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Investigators TO
-
Investigators TO. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med 2008; 358:1547-1559.
-
(2008)
New Engl J Med
, vol.358
, pp. 1547-1559
-
-
-
66
-
-
34247581728
-
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation
-
Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20:579-586.
-
(2007)
Am J Hypertens
, vol.20
, pp. 579-586
-
-
Iwai, M.1
Chen, R.2
Imura, Y.3
Horiuchi, M.4
-
67
-
-
0030480485
-
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
-
Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996; 39:5228-5235.
-
(1996)
J Med Chem
, vol.39
, pp. 5228-5235
-
-
Kohara, Y.1
Kubo, K.2
Imamiya, E.3
Wada, T.4
Inada, Y.5
Naka, T.6
-
68
-
-
34147116836
-
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system
-
Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25:951-958.
-
(2007)
J Hypertens
, vol.25
, pp. 951-958
-
-
Turnbull, F.1
Neal, B.2
Pfeffer, M.3
Kostis, J.4
Algert, C.5
Woodward, M.6
Chalmers, J.7
Zanchetti, A.8
MacMahon, S.9
|